| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00007890-199101000-00003 |
| P698 | PubMed publication ID | 1987698 |
| P50 | author | Hans Sollinger | Q89951480 |
| P2093 | author name string | A C Allison | |
| E M Eugui | |||
| D A Hullett | |||
| D E Eckhoff | |||
| K P Platz | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 27-31 | |
| P577 | publication date | 1991-01-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | RS-61443--a new, potent immunosuppressive agent | |
| P478 | volume | 51 |
| Q33602527 | A comprehensive review of immunosuppression used for liver transplantation |
| Q34346290 | Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management |
| Q36765942 | Antihypertensive agents and renal transplantation. |
| Q40830121 | Clinical islet cell transplantation. Are we there yet? |
| Q73868798 | Combination treatment effectively intercepts advanced acute cardiac rejection |
| Q44136537 | Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function |
| Q35351287 | Comparison of azathioprine with mycophenolate mofetil in a living donor kidney transplant programme |
| Q41201780 | Cyclosporine, FK-506, rapamycin, and other immunomodulators |
| Q36705722 | Cyclosporine, FK506 and other drugs in organ transplantation |
| Q73895290 | Determination of the frequency of HLA antibody secreting B-lymphocytes in alloantigen sensitized individuals |
| Q33747600 | Effect of mycophenolic acid on Epstein-Barr virus infection of human B lymphocytes |
| Q34197184 | Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures |
| Q37355472 | Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients |
| Q44941102 | Ex vivo lymphocyte proliferative function is severely inhibited in renal transplant patients on mycophenolate mofetil treatment |
| Q70706479 | Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center |
| Q34197169 | FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression |
| Q35224457 | Immunomodulatory agents in the laboratory and clinic |
| Q37634944 | Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches |
| Q44419233 | Immunosuppression with a combination of the leflunomide analog, FK778, and microemulsified cyclosporine for renal transplantation in mongrel dogs |
| Q70868868 | Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism |
| Q55068013 | Inosine-5'-monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation. |
| Q41169081 | Kidney transplantation in highly sensitized patients: reappraisal of etiology, evaluation, and management protocols |
| Q33957177 | Mycophenolate mofetil and its mechanisms of action |
| Q73838383 | Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation |
| Q44585204 | Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells |
| Q73869569 | Mycophenolate mofetil monotherapy significantly decreases the immune response of acute rejection in rat liver allografts |
| Q61654175 | Mycophenolate mofetil slows the decline of renal function in patients with biopsy-proven chronic rejection: a collaborative pilot study |
| Q34339763 | Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial |
| Q41113157 | Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation |
| Q73279418 | Mycophenolic acid in combination with FK 506: a pharmacokinetic study in piglets after small-bowel transplantation |
| Q37870314 | Mycophenolic acid in kidney transplant patients with diabetes mellitus: does the formulation matter? |
| Q58109294 | Myoblast transplantation in non-dystrophic dog |
| Q36683763 | Nephrology, dialysis and transplantation |
| Q73510082 | Nerve xenograft transplantation. Immunosuppression with FK-506 and RS-61443 |
| Q34275358 | New immunosuppressive drugs: mechanistic insights and potential therapeutic advances |
| Q67512500 | New immunosuppressive drugs: needs in and applications to pediatric transplantation |
| Q34585191 | Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy |
| Q36727064 | Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? |
| Q35653974 | Optimisation of immunosuppressive therapy using pharmacokinetic principles |
| Q35543618 | Organ allocation: model for end-stage liver disease, Child-Turcotte-Pugh, Mayo risk score, or something else |
| Q71237625 | Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats |
| Q41440241 | Post-transplant diabetes mellitus. The role of immunosuppression |
| Q41585655 | Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection |
| Q40880337 | Prevention of transplant rejection: current treatment guidelines and future developments |
| Q34288885 | Prolongation of canine renal allograft survival by combining tacrolimus with antimetabolic agents |
| Q79300100 | Prolongation of murine thyroid allografts by interleukin 2 (DAB486)-toxin and RS-61443 |
| Q67568290 | RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection |
| Q79300069 | RS-61443: successful rescue therapy in refractory renal rejection |
| Q55966493 | Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses |
| Q67531765 | Renal transplantation for the nephrologist: new immunosuppressive drugs |
| Q41502331 | Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies |
| Q35962133 | Selection of patients for liver transplantation in 1997 and beyond |
| Q55518653 | Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats. |
| Q36201852 | Steroid-free immunosuppression in organ transplantation. |
| Q36183399 | The Pharmacokinetics and Pharmacodynamics of Immunosuppressive Agents |
| Q40486220 | The changing face of liver transplantation |
| Q34350677 | The design and development of an immunosuppressive drug, mycophenolate mofetil |
| Q40432974 | The pharmacology of immunosuppressant drugs in skin transplant rejection in mice and other rodents |
| Q43442279 | The spectrum of action of new immunosuppressive drugs |
| Q35574966 | The use of mycophenolate mofetil in liver transplant recipients |
| Q33957200 | The use of mycophenolate mofetil in transplant recipients |
| Q37468247 | Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. |
| Q33965029 | Transplantation for the treatment of diabetes mellitus |
| Q77890140 | Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates |
Search more.